Bausch Health Companies (BHC) Fundamentals 2026 — Revenue Analysis | SniperIQ
Bausch Health Companies (BHC) is a CA-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Bausch Health Companies's market cap?
Bausch Health Companies (BHC) has a market capitalization of approximately
How profitable is Bausch Health Companies?
Bausch Health Companies runs a net profit margin of -11.3%, a gross margin of 61.7%, and an operating margin of 22.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Bausch Health Companies generate?
Bausch Health Companies reported revenue of
Does Bausch Health Companies pay a dividend?
Bausch Health Companies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Bausch Health Companies financially healthy?
Bausch Health Companies carries a debt-to-equity ratio of -10.10x and a current ratio of 1.32x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Bausch Health Companies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bausch Health Companies (BHC) the key facts are: market cap
Track Bausch Health Companies's full fundamentals live
Get Bausch Health Companies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.